Dual therapeutic effects of interferon-α gene therapy in a rat hepatocellular carcinoma model with liver cirrhosis

Molecular Therapy

Volumn 16, Issue 10, 2008, Pages 1681-1687

  Huang, Kai Wen ^a   Huang, Yung Chi ^a   Tai, Kuo Feng ^a,c   Chen, Bo Hua ^a   Lee, Po Huang ^a   Hwang, Lih Hwa ^a,b,d  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c TZU CHI COLLEGE OF TECHNOLOGY   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; BETA GALACTOSIDASE; DIETHYLNITROSAMINE; HYDROXYPROLINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; COMORBIDITY; CONTROLLED STUDY; DISEASE MODEL; DRUG TARGETING; GENE THERAPY; IMMUNOMODULATION; INHIBITION KINETICS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; TREATMENT OUTCOME; TUMOR VOLUME; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; APOPTOSIS; CARCINOGENS; CELL PROLIFERATION; DIETHYLNITROSAMINE; GENE THERAPY; INTERFERON-ALPHA; LIVER CIRRHOSIS; LIVER NEOPLASMS, EXPERIMENTAL; RATS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSFORMING GROWTH FACTOR BETA;

ANIMALIA; RATTUS;

EID: 54849176000     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.160     Document Type: Article

References (34)

1. Carr, BI, Bartlett, D and Marsh, JW (2001). Cancers of the liver. In: DeVita, VT, Hellman, S and Rosenberg, SA (eds.). Cancer: Principles and Practice of Oncology, 6 edn. Lippincott: Philadelphia, PA. pp. 1162-1195.
2. Okuda, H (2007). Hepatocellular carcinoma development in cirrhosis. Best Pract Res Clin Gastroenterol 21: 161-173.
3. Mohr, L, Shankara, S, Yoon, SK, Krohne, TU, Geissler, M, Roberts, B et al. (2000). Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the Escherichia coli purine nucleoside phosphorylase gene. Hepatology 31; 606-614.
4. Tatsumi, T, Takehara, T, Kanto, T, Miyagi, T, Kuzushita, N, Sugimoto, Y et al. (2001). Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma. Cancer Res 61: 7563-7567.
5. Pham-Nguyen, KB, Yang, W, Saxena, R, Thung, SN, Woo, SL and Chen, SH (1999). Role of NK and T cells in IL-12-incluced anti-tumor response against hepatic colon carcinoma. Int J Cancer 81: 813-819.
6. Chang, CJ, Tai, KF, Roffler, S and Hwang, LH (2004). The immunization site of cytokine-secreting tumor cell vaccines influences the trafficking at tumor-specific T lymphocytes and antitumor efficacy against regional tumors. J Immunol 173: 6025-6032.
7. Koen, H, Pugh, TD, Nychka, D and Goldfarb, S (1983). Presence of alpha-fetoprotein-positive cells in hepatocellular foci and microcarcinomas induced by single injections of diethylnitrosamine in infant mice. Cancer Res 43: 702-708.
8. Rajewsky, MF, Dauber, W and Frankenberg, H (1966). Liver carcinogenesis by diethylnitrosamine in the rat. Science 152: 83-85.
9. Peto, R, Gray, R, Brantom, P and Grasso, P (1991). Dose and time relationships for tumor induction in the liver and esophagus of 4080 inbred rats by chronic ingestion of N-nitrosodiethylamine or N-nitrosodimethylamine. Cancer Res 51: 6452-6469.
10. Song, KY, Lim, IK, Park, SC, Lee, SO, Park, HS, Choi, YK et al. (1999). Effect of nodularin on the expression of glutathione S-transferase placental form and proliferating cell nuclear antigen in N-nitrosodiethylamine initiated hepatocarcinogenesis in the male Fischer 344 rat. Carcinogenesis 20: 1541-1548.
11. Park, TJ, Kim, HS, Byun, KH, Jang, JI, Lee, YS and Lim, IK (2001). Sequential changes in hepatocarcinogenesis induced by diethylnitrosamine plus thioacetamide in Fischer 344 rats: Induction of gankyrin expression in liver fibrosis, pRB degradation in cirrhosis, and methylation of p16(INK4A) exon 1 in hepatocellular carcinoma. Mol Carcinog 30 138-150.
12. Solt, DB, Cayama, E, Sarma, DS and Farber, E (1980). Persistence of resistant putative preneoplastic hepatocytes induced by N-nitrosodiethylamine or N-methyl-N-nitrosourea. Cancer Res 40 1112-1118.
13. Zheng, Y, Chen, WL, Louie, SG, Yen, TS and Ou, JH (2007). Hepatitis B virus promotes hepatocarcinogenesis in transgenic mice. Hepatology 45: 16-21.
14. Friedman, SL (2000). Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 275 2247-2250.
15. Yeh, CN, Maitra, A, Lee, KF, Jan, YY and Chen, MF (2004). Thioacetamide-induced intestinal-type cholangiocarcincma in rat: An animal model recapitulating the multi-stage progression of human cholangiocarcinoma. Carcinogenesis 25: 631-636.
16. Proctor, E and Chatamra, K (1982). High yield micronodular cirrhosis in the rat. Gastroenterology 83: 1183-1190.
17. Hernandez-Munoz, R, Diaz-Munoz, M, Suarez-Cuenca, JA, Trejo-Solis, C, Lopez, V, Sanchez-Sevilla, L et al. (2001). Adenosine reverses a preestablished CCl4-induced micronodular cirrhosis through enhancing collagenolytic activity and stimulating hepatocyte cell proliferation in rats. Hepatology 34: 677-687.
18. Siller-Lopez, F, Sandoval, A, Salgado, S, Salazar, A, Buena, M, Garcia, J et al. (2004). Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis. Gastroenterology 126: 1122-1133; discussion 1949.
19. Neef, M, Ledermann, M, Saegesser, H, Schneider, V and Reichen, J (2006). Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J Hepato J 45: 786-796.
20. Morales-Gonzalez, JA, Gutierrez-Salinas, J, Yanez, L, Villagomez-Rico, C, Badillo-Romero, J and Hernandez-Munoz, R (1999). Morphological and biochemical effects of a low ethanol dose on rat liver regeneration: role of route and timing of administration. Dig Dis Sci 44: 1963-1974.
21. Sumimoto, K, Inagaki, K, Yamada, K, Kawasaki, T and Dohi, K (1988). Reliable indices for the determination of viability of grafted liver immediately after orthotopic transplantation. Bile flow rate and cellular adenosine triphosphate level. Transplantation 46: 506-509.
22. Schiffer, E, Housset, C, Cacheux, W, Wendum, D, Desbois-Mouthon, C, Rey, C et al. (2005). Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 41: 307-314.
23. Hara, H, Kobayashi, A, Yoshida, K, Ohashi, M, Ohnami, S, Uchida, E et al. (2007). Local interferon-alpha gene therapy elicits systemic immunity in a syngeneic pancreatic cancer model in hamster. Cancer Sci 98: 455-463.
24. Indraccolo, S, Tisato, V, Tosello, V, Habeler, W, Esposito, G, Moserle, L et al. (2005). Interferon-alpha gene therapy by lentiviral vectors contrasts ovarian cancer growth through angiogenesis inhibition. Hum Gene Ther 16: 957-970.
25. Inagaki, Y, Nemoto, T, Kushida, M, Sheng, Y, Higashi, K, Ikeda, K et al. (2003). Interferon alfa down-regulates collagen gene transcription and suppresses experimental hepatic fibrosis in mice. Hepatology 38: 890-899.
26. Suzuki, K, Aoki, K, Ohnami, S, Yoshida, K, Kazui, T, Kato, N et al. (2003). Adenovirus-mediated gene transfer of interferon alpha improves dimethylnitrosamine-induced liver cirrhosis in rat model. Gene Ther 10: 765-773.
27. Berasain, C, Castillo, J, Prieto, J and Avila, MA (2007). New molecular targets for hepatocellular carcinoma: The ErbB1 signaling system. Liver Int 27: 174-185.
28. Breitkopf, K, Haas, S, Wiercinska, E, Singer, MV and Dooley, S (2005). Anti-TGF-beta strategies for the treatment of chronic liver disease. Alcohol Clin Exp Res 29: 121S-131S.
29. Lin, SM, Yu, ML, Lee, CM, Chien, RN, Sheen, IS, Chu, CM et al. (2007). Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 46: 45-52.
30. Poynard, T, Leroy, V, Cohard, M, Thevenot, T, Mathurin, F, Opolon, P et al. (1996). Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration. Hepatology 24: 778-789.
31. Iredale, JP (2007). Models of liver fibrosis: Exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 117: 539-548.
32. Ferrantini, M, Capone, I and Belardelli, F (2007). Interferon-alpha and cancer: Mechanisms of action and new perspectives of clinical use. Biochimie 89: 884-893.
33. Pfeffer, LM, Dinarello, CA, Herberman, RB, Williams, BR, Borden, EC, Bordens, R et al. (1998). Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 58: 2489-2499.
34. Lee, HS, Shun, CT, Chiou, LL, Chen, CH, Huang, GT and Sheu, JC (2005). Hydroxyproline content of needle biopsies as an objective measure of liver fibrosis: Emphasis on sampling variability. J Gastronterol Hepatol 20: 1109-1114.